The following is a summary of the Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript:
Financial Performance:
Legend Biotech reported net trade sales of $157 million for the first quarter of 2024, marking a 100% year-on-year increase in sales from CARVYKTI.
There was a slight decrease from $159 million in Q4 2023 due to order timing and manufacturing testing.
Research and development expenses increased to $101 million in Q1 2024, up from $84.9 million in Q1 2023.
As of March 2024, Legend Biotech had a cash balance of $1.3 billion.
Company expects to attain operating profit by 2026 and may consider additional capital raises depending on business development.
Business Progress:
CARVYKTI received approval from major health regulatory bodies, widening its potential patient base to 80,000 across significant markets.
The company plans to double production capacity for CARVYKTI by the end of 2024 and reach 10,000 patient slots capacity by the end of 2025.
The number of US hospitals certified to administer CARVYKTI has increased to 72, expanding its reach into the community.
Trials for triple targeted CAR-T treatment are underway in China, with an expansion into autoimmune disease indications in the US planned.
Legend Biotech plans to increase capital investment to support business expansion, indicating positive business progress.
More details: Legend Biotech IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
以下是傳奇生物科技 (LEGN) 2024 年第一季度業績電話會議記錄摘要:
財務業績:
傳奇生物科技報告稱,2024年第一季度的淨貿易銷售額爲1.57億美元,標誌着CARVYKTI的銷售額同比增長了100%。
與2023年第四季度的1.59億美元相比,由於訂單時間和生產測試的原因,銷售額略有下降。
研發費用從2023年第一季度的8,490萬美元增加到2024年第一季度的1.01億美元。
截至2024年3月,聯想生物的現金餘額爲13億美元。
公司預計到2026年將實現營業利潤,並可能根據業務發展考慮額外籌集資金。
業務進展:
CARVYKTI獲得了主要衛生監管機構的批准,將其在重要市場的潛在患者基礎擴大到8萬人。
該公司計劃到2024年底將CARVYKTI的產能翻一番,到2025年底達到10,000個患者席位的產能。
獲得CARVYKTI認證的美國醫院數量已增加到72家,從而將其覆蓋範圍擴大到社區。
中國正在進行三靶向CAR-T治療的試驗,並計劃在美國擴大到自身免疫性疾病的適應症。
Legend Biotech計劃增加資本投資以支持業務擴張,這表明業務取得了積極進展。
更多詳情: 傳奇生物科技 IR
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。